CDS022564
厄洛替尼盐酸盐
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C22H24ClN3O4
化学文摘社编号:
分子量:
429.90
UNSPSC Code:
12352200
PubChem Substance ID:
MDL number:
NACRES:
NA.21
Form:
solid
description
AldrichCPR
form
solid
SMILES string
C#CC1=CC(NC2=NC=NC3=CC(OCCOC)=C(OCCOC)C=C32)=CC=C1.Cl
InChI
1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
InChI key
GTTBEUCJPZQMDZ-UHFFFAOYSA-N
Gene Information
human ... EGFR(1956)
General description
酸厄洛替尼是一种强效表皮生长因子受体（EGFR）酪氨酸激酶抑制剂。它抑制EGFR蛋白，这可能有助于预防癌细胞的生长。它还可与盐酸吉西他滨一起使用。
Other Notes
请注意，Sigma-Aldrich将此产品作为一系列独特化学品的一部分提供给早期发现的研究人员。Sigma-Aldrich不会收集该产品的分析数据。买方承担确认产品标识和纯度的责任。所有销售均为最终销售。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
尽管SIGMA-ALDRICH的标准条款和条件以及SIGMA-ALDRICH和买方之间的协议中包含所有合同条款，但无论是在法律、交易过程、执行过程中的行为、以及贸易或其他方面的使用等过程中，SIGMA-ALDRICH按“原样”销售此产品并且并对此产品不作任何陈述或担保，包括：(A)适销性担保；(B)特定用途适用性担保；或(C)未侵犯第三方知识产权担保。
Still not finding the right product?
Explore all of our products under 厄洛替尼盐酸盐
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 4
存储类别
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
Valentina Fustaino et al.
Oncotarget, 8(61), 103340-103363 (2017-12-22)
Increasing evidence points to a key role played by epithelial-mesenchymal transition (EMT) in cancer progression and drug resistance. In this study, we used
Kyu-Mok Hwang et al.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 131, 99-110 (2019-02-05)
This study focuses on improving the manufacturing process for a generic immediate-release tablet containing erlotinib hydrochloride by adding a fines recycling process during roller compaction. Due to the large fraction of small-sized API particles, the starting powder mixture was inconsistently
Yuping Liu et al.
International immunopharmacology, 69, 79-87 (2019-01-27)
Cutaneous toxicities are the commonest side effects in patients with cancer treated using epidermal growth factor receptor inhibitors such as erlotinib. For patients with such toxicities, there is a lack of safe, effective pharmacological agents. Here we established a skin
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| CDS022564-10MG | 04061828994069 |